echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > BJH: Immunogenicity and safety of BNT162b2 mRNA COVID-19 vaccine in recipients of hematopoietic stem cell transplantation

    BJH: Immunogenicity and safety of BNT162b2 mRNA COVID-19 vaccine in recipients of hematopoietic stem cell transplantation

    • Last Update: 2021-11-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Pfizer -BioNTech BNT162b2 mRNA vaccine in allogeneic hematopoietic stem cell transplantation (HSCT) recipients of immune immunogenicity and safety is not clear


    Pfizer -BioNTech BNT162b2 mRNA vaccine in allogeneic hematopoietic stem cell transplantation (HSCT) recipients of immune immunogenicity and safety is not clear


    Security, security, safety

    No serious adverse events (AE) related to vaccines were observed in the study


    Adverse event (AE) P

    Immunogenicity of BNT162b2 after vaccination

    Immunogenicity of BNT162b2 after vaccination

    At a median time of 28 days (IQR 8-69) after the second vaccination, 118 patients (77·6%) developed RBD IgG with a GMT of 2.


    P P

    Multivariate logistic regression model of RBD IgG positivity between HSCT recipients and immune normal controls (n= 424)


    Multivariate logistic regression model of RBD IgG positivity between HSCT recipients and immune normal controls (n= 424)


    CI, confidence interval; HSCT, hematopoietic stem cell transplantation; IgG, immunoglobulin G; RBD, receptor binding domain

    IgG quantification after the second vaccination of BNT162b2 vaccine in HSCT recipients and immunocompetent medical staff controls


    IgG quantification after the second vaccination of BNT162b2 vaccine in HSCT recipients and immunocompetent medical staff controls


    The study found that there is a high correlation between RBD binding IgG and NA, r= 0·70 (95% CI 0·59, 0·78; P<0·0001) (Figure2 ) r P (Figure2 )

    Correlation between RBD IgG and logarithmic transformed neutralizing antibodies


    Correlation between RBD IgG and logarithmic transformed neutralizing antibodies


    After the second vaccination, no patients in the cohort were infected with SARS-CoV-2, and the median follow-up time was 108 (104-114) days


    In summary, the BNT162b2 mRNA vaccine is safe and effective in HSCT recipients, especially those without immunosuppression


    Original source:

    Shem-Tov, N.


    Shem-Tov, N.




    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.